Name:	ACC-001
Therapeutic Applications:	Mild to moderate Alzheimer Disease
Therapy Types:	Protein: active immunization, peptide vaccine
Development Status:	investigational in U.S.
FDA Phase:	Phase II/IIa/IIb
Primary Medical Role:	ACC-001 is an Aβ(1-6) fragment attached to a carrier protein, using the surface-active saponin adjuvant QS-21, intended to help induce an antibody response against Aβ.
Role in Alzheimer's Disease:	ACC-001 is a short amino-terminal Aβ(1-6) fragment that is derived from the N-terminal B cell epitope of Aβ while avoiding T cell activation (reviewed in Lemere and Masliah 2010). This vaccine aims to avoid the safety concerns associated with AN1792 vaccine (Aβ1-42) that implicated residues Aβ15-42, the most common T cell epitope, as the cause of Th1 lymphocyte activation and predominantly responsible for autoimmune meningoencephalitis. Elan research indicates that antibodies specific for Aβ peptide can cross the blood-brain barrier and act directly in the central nervous system to induce plaque clearance. These findings suggest that this novel method may clear plaques in human patients.
Companies:	Elan Corporation, Janssen Pharmaceuticals, Pfizer, Inc.
Notes:	Currently six Phase II trials of ACC-001 are recruiting participants. For the full list see ACC-001 trials. This record was updated January 13, 2012.

References

Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010 Feb;6(2):108-19. Review. Erratum in: Nat Rev Neurol. 2010 Apr;6(4):183. Nat Rev Neurol. 2010 Jun;6(6):296. POW Link